Effects of Yigan Tiaozhi Decoction on Serum NO, Endotoxin and RBP4 in Patients with Nonalcoholic Fatty Liver Disease

OBJECTIVE: To explore the effects of Yigan Tiaozhi Decoction on serum nitric oxide(NO), endotoxin and retinol binding protein 4(RBP4) in patients with nonalcoholic fatty liver disease(NAFLD), and to provide evidence for clinical treatment of such patients. METHODS: A total of 92 patients with NAFLD admitted to Army General Hospital 263 Clinic from March 2013 to March 2017 were selected, and all patients were divided into the control group(n = 46) and the observation group(n = 46) according to the random number table method. The patients in the control group were given conventional treatment, and the patients in the observation group were treated with Yigan Tiaozhi Decoction on the basis of the control group. Liver function, blood lipid levels, serum NO, endotoxin, RBP4 levels and clinical efficacy were observed and compared between the 2 groups before and after treatment. RESULTS: Before treatment, there was no significant difference in serum alanine aminotransferase, glutamyltranspeptidase, aspartate aminotransferase, total cholesterol and triglyceride levels between the 2 groups(P > 0.05); after treatment, the serum levels of alanine aminotransferase, glutamyltranspeptidase, aspartate aminotransferase, total cholesterol and triglyceride in the observation group were lower than those in the control group, and the difference was statistically significant(P < 0.05); before treatment, there was no significant difference in serum NO, endotoxin and RBP4 levels between the 2 groups(P > 0.05); after treatment, the serum NO, endotoxin and RBP4 levels in the observation group were lower than those in the control group, and the difference was statistically significant(P < 0.05); the total effective rate of treatment in the observation group(89.13%) was significantly higher than that in the control group(76.09%), and the difference was statistically significant(P < 0.05). CONCLUSION: Yigan Tiaozhi Decoction is effective in NAFLD, which can reduce serum NO, endotoxin and RBP4 levels, improve liver function and reduce blood lipid levels.

灵芝调脂茶对高血压合并高脂血症患者代谢指标及肾素-血管紧张素-醛固酮系统的影响探讨

目的 观察灵芝调脂茶对高血压合并高脂血症患者代谢指标及肾素-血管紧张素-醛固酮系统(RAAS)的影响。方法 101例高血压合并高脂血症患者为研究对象,按照随机数字表法分为治疗组(57例)和对照组(54例)。两组均指导健康生活方式,对照组口服苯磺酸氨氯地平、瑞舒伐他汀治疗,治疗组在对照组基础上饮用灵芝调脂茶。比较两组治疗前后空腹血糖(FPG)、血脂指标[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、尿酸(UA)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、RAAS[肾素活性(PRA)、血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)]。结果 两组治疗后TC、TG、LDL-C水平均较治疗前明显下降, HDL-C水平上升,且治疗组FPG、UA水平较治疗前明显下降,差异有统计学意义(P<0.05);对照组治疗后FPG、UA水平与治疗前比较无明显统计学意义(P>0.05);相比对照组,治疗组治疗后TC、TG、LDL-C水平下降更为显著, HDL-C水平上升更为明显,差异有统计学意义(P<0.05);两组治疗后FPG、UA组间比较无明显统计学意义(P>0.05)。两组治疗后FINS及HOMA-IR较治疗前均有下降,差异有统计学意义(P<0.05);治疗组治疗后FINS(89.51±33.00)pmol/L、HOMA-IR(3.16±1.44)均低于对照组的(104.09±38.76)pmol/L、(3.81±1.67),差异有统计学意义(P<0.05)。治疗组治疗后PRA、AngⅡ、ALD均较治疗前明显下降,差异有统计学意义(P<0.05);对照组治疗前后PRA无显著性差异(P>0.05);对照组治疗后AngⅡ、ALD均较治疗前明显下降,差异有统计学意义(P<0.05)。治疗组治疗后PRA(1.61±0.74)ng/(ml·h)、AngⅡ(87.19±10.05)pg/ml、ALD(112.08±30.85)pg/ml均低于对照组的(2.02±0.32)ng/(ml·h)、(93.08±14.80)pg/ml、(128.25±25.25)pg/ml,差异有统计学意义(P<0.05)。两组患者治疗期间均未发生严重不良反应。结论 灵芝调脂茶治疗高血压合并高脂血症疗效确切,能有效控制血脂,改善HOMA-IR,调节RAAS系统,安全性好,是值得临床广泛使用的中药制剂。

健脾化浊调脂颗粒的化学成分及入血成分分析

目的分析健脾化浊调脂颗粒(JHTG)的化学成分及其入血成分。方法将SD大鼠分为对照组和给药组,每组6只。给药组大鼠灌胃JHTG药液3 mL。灌胃60 min后,收集两组大鼠血清样品,采用超高效液相色谱-串联质谱技术对JHTG的化学成分及入血成分进行色谱分离和质谱数据采集,结合UNIFI天然产物整体解决方案,基于6400天然产物理论质谱数据库并通过文献查阅、对照品比对等进行结构分析、确认。结果与结论从JHTG中共鉴定出130个成分,其中党参3个、荷叶13个、茯苓15个、白术5个、陈皮9个、薏苡仁1个、泽泻19个、丹参24个、麦芽7个、山楂24个、砂仁2个、木香3个,另外槲皮素、槲皮素-3-O-β-D-吡喃葡萄糖苷、山柰黄素、柠檬酸可能来源于荷叶或山楂,土当归酸可能来源于茯苓或山楂;通过与对照品比对,最终确定了8个成分(茯苓酸、白术内酯Ⅱ、泽泻醇A、泽泻醇B、土木香内酯、乙酸龙脑酯、丹酚酸A、丹酚酸C)。共鉴定出槲皮素、山柰黄素等72个入血原型成分,以黄酮类、萜类、木脂素类、酚酸类成分为主。共鉴定出去氢番荔枝碱、16-氧乙酰茯苓酸等11个代谢产物,以萜类成分为主;代谢途径包括脱氢、脱羟基等Ⅰ相代谢反应及甲基化、乙酰化等Ⅱ相代谢反应。

Effect of Tiaozhi Yanggan Decoction(调脂养肝汤)in Treating Patients with Non-alcoholic Fatty Liver

Objective： To observe the clinical efficacy and safety of Tiaozhi Yanggan Decoction （调脂养肝汤,TZYGD） in treating non-alcoholic fatty liver. Methods： One hundred and thirty-eight patients were enrolled and randomized into two groups according to the random number table in a ratio of 3：1, with 8 cases eventually dropping out. The symptoms, signs, liver function markers, blood lipids, iconographic indices and clinical comprehensive efficacy after a 12-week treatment course were assessed in 101 patients treated with TZYGD in the treated group and 29 patients treated with Thiola in the control group. Results： The total effective rate in the treated group and the control group was 81.19% and 68.97%, respectively, showing a significant difference between the two groups with the former being significantly higher than the latter （P〈0.05）. Moreover, the improvements in the symptoms, signs, liver function, blood lipids and iconographic indices in the treated group were favorable with no serious adverse reactions. Conclusion： TZYGD is effective and highly safe in treating non-alcoholic fatty liver.

Simultaneous Determination of Seven Alkaloids in Fufang Zhenzhu Tiaozhi Capsule by HPLC Coupled with DAD

Objective To establish a reverse-phase liquid chromatography method for the determination of seven alkaloids (magnoflorine, columbamine, jatrorrhizine, epiberberine, coptisine, palmatine, and berberine) in Fufang Zhenzhu Tiaozhi Capsule. Methods Chromatography was performed on a Dionex Acclaim C 18 column (250 mm × 4.6 mm, 5.0 μm) at 30 ℃ .The mobile phase was composed of acetonitrile-potassium dihydrogen phosphate solution (0.015 mol/L, 40:60, including 1.7 g/L sodium dodecyl sulfate and phosphoric acid used to regulate pH value to 3.0), with a flow rate of 1.0 mL/min. The detection wavelength was 270 nm. Results The calibration curves of magnoflorine, columbamine, jatrorrhizine, epiberberine, coptisine, palmatine, and berberine were linear in the range of 1.07- 10.65, 0.78-7.55, 0.75-7.50, 1.60-15.95, 2.69-26.85, 2.31-23.10, and 6.04-60.40 mg/mL. The average recoveries of magnoflorine, columbamine, jatrorrhizine, epiberberine, coptisine, palmatine, and berberine were 101.0%, 101.2%, 100.1%, 100.0%, 100.1%, 101.1%, and 99.7%, respectively. Conclusion The method could be used for the quantitative determination of the preparation.

Experimental Study of Yishou Tiaozhi Tablet(益寿调脂片) on Inhibiting Hyperlipemia and Atherosclerosis

Objective: To observe the effect of Yishou Tiaozhi tablet(YSTZT) on lipid metabolism and aortic intimal atherosclerotic plaque coverage in rabbit model of experimental hyperlipemia and atherosclerosis.Methods: Thirty two rabbits were randomly divided into four groups, Group A, B, C and D, 8 in each group. Forage with cholesterol and lipid plus 1.59 g/kg of YSTZT was fed to Group A every day;for Group B, 22.54 mg/kg gypenoside tablet was added to forage with cholesterol and lipid; for Group C, hyperlipid forage was given and for Group D, only ordinary forage was given. Biochemical parameters were measured and pathomorphological examinations were carried out 6 weeks later.Results: (1) YSTZT obviously lowered the levels of serum total cholesterol(TC), triglyceride(TG), atherosclerotic index(AI), apoprotein(ApoB), lipoprotein [Lp(a)], oxygen low density lipoprotein cholesterol(ox LDL), hydroxyproline(HYP), plasma Ca 2+ , thromboxane B 2(TXB 2), and increased the levels of serum high density lipoprotein cholesterol(HDL C), apoprotein A 1(Apo A 1), ApoA 1 /ApoB, plasma 6 keto PGF 1α ( P <0.01). (2) Pathomorphological examination showed that in Group A aortic intimal atherosclerotic plaque area and arterial intima thickness were obviously reduced, smooth muscle cell hyperplasia and elastic fibers were not seen.Conclusion: YSTZT can inhibit experimental hyperlipemia and atherogenesis. It is an ideal and effective medicine in preventing and treating hyperlipemia and atherosclerosis.

Experimental Study of Yishou Tiaozhi Tablet(益寿调脂片) on Free Radical Metabolism in Aging Model Mice

Objective： To observe the effect of Yishou Tiaozhi tablet（YSTZT） on the metabolism of free radical in mice of aging model. Methods: Using the aging model induced by hypodermic injection of 5%D-glalactose in mice for forty days. The content of malondialdehyde(MDA) and activity of superoxide dismutase(SOD), glutathione peroxidase (GSH-Px) in serum, activity of monoamine oxidase B (MAO-B), Na+-K+-ATPase in brain were investigated after treatment. Results: Compared with the aging model group, it showed that YSTZT could obviously inhibit the increase of level of MDA in serum and the activities of MAO-B in brain; and enhance the activities of SOD,GSH-Px in serum, and the activities of Na+-K+-ATPase in brain. Furthermore, YSTZT could obviously elevate the tolerance to fatigue and hypoxia in mice. Conclusion: YSTZT could effectively improve the free radical metabolism of senile body, it is an ideal and effective medicine in preventing aging, which is also one of the experimental basis in proving the theory of 'Spleen and Kidney Deficiency complicated with Stasis and Phlegm causes aging'.

Jianpi Huazhuo Tiaozhi granules reduce oxidative stress injury in macrophages by inhibiting the nicotinamide adenine dinucleotide phosphate oxidase/reactive oxygen species-nuclear transcription factor kappa B pathway

OBJECTIVE:To assess the effect of Jianpi Huazhuo Tiaozhi granules(JHTG)on oxidative stress damage to macrophages and explore the relationship between the levels of this damage and the nicotinamide adenine dinucleotide phosphate oxidase(NOX)/reactive oxygen species(ROS)-nuclear transcription factor kappa B(NF-κB)signaling pathway.METHODS:Macrophages cultured in vitro were divided into seven groups:control,model control,inhibitor,positive control,2.5%JHTG,5%JHTG,and10%JHTG.An oxidative stress injury model was established by stimulating macrophages with oxidized low-density lipoprotein.Cell survival and apoptosis were detected by 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide and flow cytometry assays,respectively.Malondialdehyde and superoxide dismutase levels were detected by enzyme-linked immunosorbent assays,while ROS levels were detected using a fluorescence probe.Proteins and m RNAs associated with the NOX/ROS-NF-κB pathway,including NOX4,p22 phox,inhibitor of NF-κB kinase-α(IKK-α),inhibitor of NF-κB kinase-β(IKK-β),and NF-κB were detected by Western blot and PCR,respectively.RESULTS:After JHTG treatment,there were fewer damaged and apoptotic macrophages,while superoxide dismutase levels were elevated.The JHTG-treated groups also showed reduced ROS levels.The molecular changes following JHTG treatment included decreased expression of NOX4 and p22 phox at the protein level and decreased IKK-α,IKK-β,and NF-κB expression at the m RNA level.All of these effects were correlated with the JHTG concentration.CONCLUSION:These results demonstrated that the molecular mechanism underlying the antioxidant activity of JHTG in macrophages is through inhibiting the NOX/ROS-NF-κB pathway.

调治天癸方治疗特发性少弱精子症的临床观察

目的观察调治天癸方治疗特发性少弱精子症的临床疗效。方法选取2020年6月至2021年6月湖南中医药大学第一附属医院男性病科门诊就诊的80例特发性少弱精子症患者作为研究对象,随机分为调治天癸组和五子衍宗组,每组40例,分别用调治天癸方与五子衍宗软胶囊干预12周,治疗前后观察精液常规、精子DNA碎片指数(DFI)的改善情况及配偶的受孕情况。结果治疗前两组患者的精子密度、前向运动精子率(PR)及DFI均无明显差异。治疗结束后,两组患者精子密度、PR、DFI均较治疗前有所改善(P<0.05),且调治天癸组精子质量及DFI的改善情况优于五子衍宗组(P<0.05)。调治天癸组有7位患者配偶妊娠,总有效率87.50%,五子衍宗组有4位患者配偶妊娠,总有效率67.50%,两组总有效率比较,差异具有统计学意义(P<0.05)。结论调治天癸方可提高特发性少弱精子症患者的精子密度、PR,减少精子DNA碎片化,且无明显不良反应。

健脾化浊调脂颗粒调节肠道菌群紊乱治疗动脉粥样硬化的研究

目的 观察健脾化浊调脂颗粒在动脉粥样硬化(AS)治疗中的效果。方法 选取100例AS患者,以随机数字表法分成对照组(阿托伐他汀钙片与阿司匹林肠溶片治疗)和观察组(对照组基础上联合健脾化浊调脂颗粒),每组50例。比较2组疗效。结果 治疗后,观察组TC、TG、LDL-C指标低于对照组,HDL-C指标高于对照组;IMT、斑块数量及斑块厚度低于对照组;TMAO指标高于对照组;CRP、IL-6、TNF-ɑ指标低于对照组;临床治疗有效率高于对照组,差异均有统计学意义(P<0.05)。结论 AS疾病使用健脾化浊调脂颗粒治疗,有助于改善患者脂代谢指标,缩小斑块厚度,优化血清指标,治疗效果突出。

健脾化浊调脂颗粒调节肠道菌群紊乱治疗动脉粥样硬化的临床研究

目的 研究健脾化浊调脂颗粒通过调节肠道菌群紊乱治疗动脉粥样硬化(AS)的临床效果。方法 选取江西中医药大学附属医院2021年1月—2021年12月诊治的100例AS患者,以随机抽签法均分为参照组和治疗组(各50例)。全部患者接受常规健康指导,参照组采取阿托伐他汀钙片联合阿司匹林肠溶片治疗,治疗组在此基础上口服健脾化浊调脂颗粒。观察治疗后患者血脂水平、炎症因子变化。结果 治疗3个月后,治疗组三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)水平均低于参照组,高密度脂蛋白(HDL-C)水平高于参照组(P<0.05);治疗组白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)均低于参照组(P<0.05)。结论 健脾化浊调脂颗粒可通过调节肠道菌群紊乱治疗动脉粥样硬化,改善患者血脂状态,减轻炎症对身体的影响。

王枣荷叶调脂汤联合穴位贴敷治疗痰瘀互结型非酒精性脂肪性肝病疗效及对血清SOD、MDA的影响

目的:探讨王枣荷叶调脂汤联合穴位贴敷对非酒精性脂肪性肝病(NAFLD)痰瘀互结型患者的临床疗效及对血清SOD、MDA的影响。方法:选取2020年6月至2021年7月的痰瘀互结型NAFLD患者90例,按随机数字表法分为两组,每组45例。对照组患者给予常规治疗,治疗组患者在对照组患者治疗基础上给予王枣荷叶调脂汤联合穴位贴敷治疗,12周后观察两组患者治疗前后中医证候积分、超声分级、BMI、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、甘油三酯(TG)、胆固醇(TC)、超氧化物歧化酶(SOD)、丙二醛(MDA)、胰岛素抵抗指数(HOMA-IR)水平,并判定临床疗效。结果:治疗12周后治疗组患者临床总有效率明显优于对照组,肝脏超声有效率高于对照组;两组患者BMI指数及中医证候积分均较治疗前改善,治疗组患者优于对照组(P<0.05);两组患者ALT、AST、TC、TG、SOD、MDA水平均显著优于治疗前(P<0.01),且治疗组患者优于对照组(P<0.05);治疗组患者HOMA-IR明显低于治疗前(P<0.01)。结论:王枣荷叶调脂汤联合穴位贴敷可缓解痰瘀互结型NAFLD患者症状,改善体征,促进肝功能恢复,降低血脂水平,改善肝脏糖脂代谢,减轻患者体重,具有一定抗氧化应激及抗炎症反应作用。

丹栀调脂汤对高脂诱导MAFLD大鼠PI3K/AKT/FOXO1信号通路的影响

目的研究丹栀调脂汤对高脂饮食诱导的代谢相关脂肪性肝病(MAFLD)大鼠PI3K/AKT/FOXO1信号通路的影响,探讨其在MAFLD治疗中的作用。方法雄性SD大鼠分为正常组、模型组及丹栀调脂汤高、中、低剂量组。正常组和模型组予等体积的生理盐水,丹栀调脂汤高、中、低剂量组分别予丹栀调脂汤20.4、10.2、5.1 g·kg^(-1)·d^(-1),连续灌胃8周后取材。检测5组大鼠体质量、血脂、血糖、胰岛素水平及HOMA-IR变化情况;肝脏组织脂质沉积情况;Western blot检测PI3K/AKT信号通路中各蛋白表达水平。结果与正常组比较,模型组大鼠体质量、TG、TC、FFA、GLU、INS、LDL-C及HOMA-IR水平明显升高,HDL-C水平明显降低;肝脏组织油红O染色可见明显肿大的肝细胞及明显的脂质沉积;PI3K、AKT蛋白磷酸化表达水平显著降低。相较于模型组,丹栀调脂汤高、中、低剂量组体质量、TG、TC、FFA、GLU、INS、LDL-C及HOMA-IR水平不同程度降低;肝细胞肿大、肝细胞脂滴及排列结构均有不同程度的改善;PI3K、AKT、FOXO1蛋白磷酸化表达水平升高。结论丹栀调脂汤可能通过PI3K/AKT/FOXO1信号通路改善胰岛素抵抗,进而达到防治MAFLD的目的。

复方贞术调脂胶囊通过TLR4/NF-κB通路改善脂多糖诱导的小鼠急性肝损伤

目的探讨复方贞术调脂胶囊(FTZ)对脂多糖(LPS)诱导的急性肝损伤的保护作用及机制。方法将SPF级雄性BALB/c小鼠分为正常(Normal)组、模型(Model)组、FTZ低剂量(FTZ-L)组、FTZ中剂量(FTZ-M)组、FTZ高剂量(FTZ-H)组和阳性对照(Positive control)组,每组8只。Normal组和Model组灌胃给予0.5%CMC-Na,FTZ低、中、高剂量组分别给予0.5、1、2 g·kg^(-1)的FTZ混悬液,Positive control组给予1.3 mg·kg^(-1)的醋酸泼尼松龙。所有动物进行灌胃给药1周后,采用腹腔注射LPS(5 mg·kg^(-1))建立急性肝损伤模型,造模6 h后取血和肝脏标本。采用酶标仪测定血清ALT、AST、TNF-α、IL-1β、IL-6、IL-8、IL-17和内毒素水平;HE法观察肝组织病理学改变;免疫荧光法检测中性粒细胞(Ly-6G+)浸润情况;Western Blot检测TLR4、NF-κB、p-NF-κB、IκB和p-IκB的蛋白表达水平。结果与Model组相比,FTZ干预能够显著降低小鼠ALT、AST、TNF-α、IL-1β、IL-6、IL-8、IL-17和内毒素水平,改善肝静脉出血和炎性细胞浸润,减少Ly-6G+中性粒细胞数量,抑制TLR4、p-NF-κB和p-IκB蛋白的表达。结论FTZ能有效改善LPS诱导的小鼠急性肝损伤,其机制可能与抑制内毒素及TLR4/NF-κB信号通路的激活相关。

通络调脂汤治疗动脉粥样硬化临床观察

目的 研究通络调脂汤运用于动脉粥样硬化中的价值。方法 选择江西省万安县人民医院2020年6月-2021年9月收治的74例动脉粥样硬化患者,按随机数字表法分为2组,各37例。汤剂组服用通络调脂汤,参照组选择常规治疗,比较2组的用药结果。结果 汤剂组总有效率89.19%(33/37)高于参照组的70.27%(26/37)(P<0.05)。汤剂组不良反应发生率8.11%(3/37)与参照组的13.51%(5/37)对比,差异无统计学意义(P>0.05)。服药前2组血脂、心功能、肠道菌群指标差异无统计学意义(P>0.05);服药后汤剂组三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、室间隔厚度(IVST)、左室后壁厚度(LVPWT)、大肠杆菌水平低于参照组,但高密度脂蛋白(HDLC)、左室射血分数(LVEF)、心排血量(CO)、乳杆菌、双歧杆菌水平高于参照组(P<0.05)。结论 通络调脂汤治疗动脉粥样硬化的效果显著,值得推广。

基于质量源于设计理念的调脂柔脉颗粒制备工艺研究

目的基于质量源于设计(Quality by Design,QbD)理念优化调脂柔脉颗粒的处方配比及制备工艺并建立其有效成分的含量测定方法。方法通过单因素试验确定最佳处方组成,结合鱼骨图以及失效模式及效应分析(Failure mode and effect analysis,FMEA)确定调脂柔脉颗粒制备过程中的关键工艺参数(Critical process parameters,CPPs)和关键质量属性(Critical quality attributes,CQAs),采用Box-Behnken响应面法进一步优化制备工艺并利用HPLC法测定调脂柔脉颗粒中大黄酚、丹酚酸A两种成分的含量。结果最佳润湿剂为70%乙醇,最佳填充剂为α-乳糖与糊精按1∶2合用,最佳处方比例为主药∶稀释剂∶黏合剂为4∶12∶5.5;最优条件下制备的调脂柔脉颗粒中大黄酚含量为0.716 mg·g^(-1),丹酚酸A的含量为0.525 mg·g^(-1),成型率大于82.23%,颗粒剂质量检查符合标准。结论基于QbD理念的调脂柔脉颗粒制备工艺稳定可行,质量稳定可控。

复方贞术调脂胶囊对兔动脉粥样硬化模型脂质代谢的影响

目的:观察复方贞术调脂胶囊(FTZ)对实验性动脉粥样硬化家兔脂质代谢的影响。方法:将50只家兔分为正常对照组、模型组、辛伐他汀阳性对照组及FTZ高、低剂量组,每组10只。采用高脂饮食法建立兔动脉粥样硬化(AS)模型,给药组在喂高脂饲料的同时每天给予相应的药物,连续喂养12 w。检测实验前、实验第4、8、12周的血脂水平,于实验末测定血清载脂蛋白水平、肝脏脂质含量以及主动脉内膜斑块面积比。结果:FTZ能显著降低AS家兔血清的TC、TG、LDL-C、ApoB水平(P<0.05或P<0.01),升高HDL-C水平和ApoAⅠ/ApoB比值(P<0.05);各给药组肝脏组织中的TC、TG含量以及内膜斑块面积比显著低于模型组(P<0.05或P<0.01)。结论:FTZ能有效调节实验性动脉粥样硬化家兔的脂代谢异常,这可能是其抗动脉粥样硬化作用的主要机理。

益寿调脂片对衰老模型小鼠自由基代谢作用的实验研究

目的:观察益寿调脂片对衰老模型小鼠自由基代谢调整作用。方法:利用5%D半乳糖皮下注射40天所致亚急性衰老模型小鼠,造模同时分别给予1%淀粉溶液(空白对照组、衰老模型组)、益寿调脂片溶液(低剂抗衰组、高剂抗衰组)及绞股蓝总甙片(阳性抗衰组)40天后,观察自由基代谢指标如血清丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化酶(GSHPx)及大脑B型单胺氧化酶(MAOB)、Na+K+ATP酶改善情况。并观察益寿调脂片对不造模小鼠体能及应激能力的影响。结果:与衰老模型组比较,益寿调脂片能显著降低衰老模型小鼠的血清MDA含量及脑组织MAOB活性(P<001),而使血清SOD、GSHPx及脑组织中Na+K+ATP酶活性明显提高(P<001)。并与正常组比较,益寿调脂片能显著提高小鼠抗疲劳及耐缺氧能力,且具一定的量效关系。结论:益寿调脂片能有效的改善衰老机体自由基代谢,是理想而有效的延缓衰老的药物;并为衰老的“脾肾两虚、夹瘀夹痰”的理论提供了有力的实验依据。

益寿调脂片抗高脂血症及动脉粥样硬化的实验研究

目的 :观察益寿调脂片对兔高脂血症、动脉粥样硬化模型中脂质代谢和主动脉内膜斑块形成的影响。方法 :将 3 2只家兔随机分为 4组 (每组 8只 ) :益寿调脂片组喂高脂饲料加益寿调脂片 1 5 9g·kg- 1 ·d- 1 ,绞股蓝总甙片组喂高脂饲料加绞股蓝总甙片 2 2 5 4mg·kg- 1 ·d- 1 ,高脂组喂高脂饲料 ,正常组喂普通饲料 ,6周后测定有关生化指标并进行病理形态学检查。结果 :(1 )益寿调脂片组血清总胆固醇 (TC)、甘油三酯 (TG)、动脉粥样硬化指数 (AI)、载脂蛋白B(ApoB)、脂蛋白 (a)〔Lp(a)〕、氧化型低密度脂蛋白 (ox LDL)、羟脯氨酸 (HYP)、钙离子浓度(Ca2 +)、血栓素B2 (TXB2 )均较绞股蓝总甙片组和高脂组明显降低 (P <0 0 0 1 ) ,而血清高密度脂蛋白胆固醇 (HDL C)、载脂蛋白A1 (ApoA1 )、6 酮 前列腺素F1α(6 keto PGF1α)及ApoA1 /ApoB比值明显升高 (P <0 0 0 1 )。 (2 )病理形态学检查显示益寿调脂片组兔主动脉斑块面积明显减少 ,动脉内膜增厚不明显 ,未见显著的平滑肌细胞增生及弹力纤维形成。结论 :益寿调脂片能对抗实验性高脂血症及动脉粥样硬化的形成 ,是防治高脂血症、动脉粥样硬化理想而有效的药物。

益寿调脂片调脂和抗自由基损伤的研究

为观察具有益气健脾、滋补肝肾、除湿化痰、理气活血功效的中成药益寿调脂片（由黄芪、丹参、枸杞子、何首乌、大蒜等中药组成）调脂和抗自由基损伤的作用，应用益寿调脂片治疗原发性高脂血症进行临床及实验研究。结果：临床和实验结果均显示益寿调脂片能降低血清总胆固醇（ＴＣ）、甘油三酯（ＴＧ）、动脉粥样硬化指数（ＡＩ）、血浆载脂蛋白Ｂ１００（ＡｐｏＢ１００）及丙二醛（ＭＤＡ）和升高血清高密度脂蛋白胆固醇（ＨＤＬ－ｃ）、血浆载脂蛋白Ａ１（ＡｐｏＡ１）及超氧化物歧化酶（ＳＯＤ）（Ｐ＜０．００１）。表明益寿调脂片具有调脂、抗脂质过氧化物及清除氧自由基的作用。